1-(2,6-二甲基苯基)-3-(5-甲基-1,2-恶唑-3-基)脲 | 130403-16-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(2,6-二甲基苯基)-3-(5-甲基-1,2-恶唑-3-基)脲
• 英文名称: N1-(2,6-dimethylphenyl)-N2-(5-methyl-3-isoxazolyl)urea
• 英文别名: N-(2,6-dimethyl phenyl)-N'-(5-methyl 3-isoxazolyl) urea；N-(2,6-dimethyl phenyl)-N'-(5-methyl 3-isoxazolyl)-urea；Urea, N-(2,6-dimethylphenyl)-N'-(5-methyl-3-isoxazolyl)-；1-(2,6-dimethylphenyl)-3-(5-methyl-1,2-oxazol-3-yl)urea
• CAS: 130403-16-6
• 化学式: C₁₃H₁₅N₃O₂
• 分子量: 245.281
• InChiKey: HUODFDFUGXYPJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氨基-5-甲基异恶唑 、 2,6-二甲苯基异氰酸酯 以 四氢呋喃 为溶剂， 反应 48.0h， 以42%的产率得到1-(2,6-二甲基苯基)-3-(5-甲基-1,2-恶唑-3-基)脲
  参考文献：
  名称：

  New N-aryl isoxazolecarboxamides and N-isoxazolylbenzamides as anticonvulsant agents

  摘要：

  We prepared a series of N-aryl isoxazolecarboxamide, N-isoxazolylbenzamide compounds and derivatives and studied their anticonvulsant action in MES and MMS tests. Some of these reveal considerable activity, especially with respect to MES test. The disubstitution in the 2.6-position on the phenyl ring by two methyl groups would appear to be of primary importance for the activity. The amide bridge between the phenyl and isoxazolic rings, whether of the anilide or benzamide type, seems to show similar anticonvulsant behavior. We have selected the derivatives 8 (N-(2.6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide, 12 (N-(2,6-dimethylphenyl)-5-hydroxymethyl-3-isoxazolecarboxamide) and 51 (N-(5-methyl-3-isoxazolyl)-2.6-dimethylbenzamide) which are presently being studied in more extended pharmacological tests.

  DOI：

  10.1016/0223-5234(92)90137-p

文献信息

• Novel isoxazole and isoxazoline compounds with anticonvulsant activity
  申请人：Novapharme

  公开号：US05059614A1

  公开（公告）日：1991-10-22

  The object of the invention are anticonvulsant heterocyclic compounds of general formula: ##STR1## in which R.sub.1 and R.sub.2 is each selected from C.sub.1 -C.sub.4 alkyl, phenyl, benzyl, trifluoromethyl or halogen, R.sub.3 is selected from hydrogen, hydroxy, C.sub.1 -C.sub.4 alkyl or alkoxy, R.sub.4, in position 3 or 5, is selected from hydrogen, trifluoromethyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkyl, or C.sub.1 -C.sub.4 hydroxyalkyl, R.sub.5 is selected from hydrogen or C.sub.4 -C.sub.4 alkyl or R.sub.4 and R.sub.5 together form a tetramethylene group, Z at position 3 or 5 on the heterocycle is selected from: --N(R.sub.6)--CO--, --CO--N(R.sub.6)--, --N(R.sub.6)--CO--N(R.sub.6)-- --CH(R.sub.6)--NH--CO--, or --NH-CO--CH(R.sub.6), in which R.sub.6 is selected from hydrogen or C.sub.1 -C.sub.4 alkyl.

  本发明的对象是一种通式为： ##STR1## 的抗癫痫杂环化合物，其中R.sub.1和R.sub.2各自选自C.sub.1-C.sub.4烷基、苯基、苄基、三氟甲基或卤素，R.sub.3选自氢、羟基、C.sub.1-C.sub.4烷基或烷氧基，R.sub.4在3或5位选自氢、三氟甲基、C.sub.1-C.sub.4烷氧基、C.sub.1-C.sub.4烷基或C.sub.1-C.sub.4羟基烷基，R.sub.5选自氢或C.sub.4-C.sub.4烷基，或R.sub.4和R.sub.5在一起形成四亚甲基基团，杂环上3或5位的Z选自：--N(R.sub.6)--CO--、--CO--N(R.sub.6)--、--N(R.sub.6)--CO--N(R.sub.6)--、--CH(R.sub.6)--NH--CO--或--NH-CO--CH(R.sub.6)，其中R.sub.6选自氢或C.sub.1-C.sub.4烷基。
• US5059614A
  申请人：——

  公开号：US5059614A

  公开（公告）日：1991-10-22
• New N-aryl isoxazolecarboxamides and N-isoxazolylbenzamides as anticonvulsant agents
  作者：F Lepage、F Tombret、G Cuvier、A Marivain、JM Gillardin

  DOI：10.1016/0223-5234(92)90137-p

  日期：1992.9

  We prepared a series of N-aryl isoxazolecarboxamide, N-isoxazolylbenzamide compounds and derivatives and studied their anticonvulsant action in MES and MMS tests. Some of these reveal considerable activity, especially with respect to MES test. The disubstitution in the 2.6-position on the phenyl ring by two methyl groups would appear to be of primary importance for the activity. The amide bridge between the phenyl and isoxazolic rings, whether of the anilide or benzamide type, seems to show similar anticonvulsant behavior. We have selected the derivatives 8 (N-(2.6-dimethylphenyl)-5-methyl-3-isoxazolecarboxamide, 12 (N-(2,6-dimethylphenyl)-5-hydroxymethyl-3-isoxazolecarboxamide) and 51 (N-(5-methyl-3-isoxazolyl)-2.6-dimethylbenzamide) which are presently being studied in more extended pharmacological tests.